Aim: Considering the unmet need for the counseling of cancer patients treated with immune checkpoint inhibitors (CKI) about influenza vaccination, an explorative study was planned to assess flu vaccine efficacy in this population. Methods: INVIDIa was a retrospective, multicenter study, enrolling consecutive advanced cancer outpatients receiving CKI during the influenza season 2016-2017. Results: Of 300 patients, 79 received flu vaccine. The incidence of influenza syndrome was 24.1% among vaccinated, versus 11.8% of controls; odds ratio: 2.4; 95% CI: 1.23-4.59; p = 0.009. The clinical ineffectiveness of vaccine was more pronounced among elderly: 37.8% among vaccinated patients, versus 6.1% of unvaccinated, odds ratio: 9.28; 95% CI: 2.77-31.14; p < 0.0001. Conclusion: Although influenza vaccine may be clinically ineffective in advanced cancer patients receiving CKI, it seems not to negatively impact the efficacy of anticancer therapy.

INfluenza vaccine indication during therapy with Immune checkpoint inhibitors: a transversal challenge. the INVIDIa study / Bersanelli, M.; Giannarelli, D.; Castrignano, P.; Fornarini, G.; Panni, S.; Mazzoni, Federico; Tiseo, M.; Rossetti, S.; Gambale, E.; Rossi, E.; Papa, A.; Cortellini, A.; Lolli, Cristina; Ratta, R.; Michiara, M.; Milella, M.; Luca, E. D.; Soraru, M.; Mucciarini, C.; Atzori, F.; Banna, G. L.; Torre, L. L.; Vitale, M. G.; Massari, F.; Rebuzzi, S. E.; Facchini, G.; Schinzari, G.; Tomao, S.; Bui, S.; Vaccaro, V.; Procopio, G.; Giorgi, U. D.; Santoni, M.; Ficorella, C.; Sabbatini, R.; Maestri, A.; Natoli, C.; Tursi, M. D.; Maio, M. D.; Rapacchi, E.; Pireddu, Annagrazia; Sava, T.; Lipari, H.; Comito, F.; Verzoni, E.; Leonardi, F.; Buti, S.. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - 10:14(2018), pp. 1229-1239. [10.2217/imt-2018-0080]

INfluenza vaccine indication during therapy with Immune checkpoint inhibitors: a transversal challenge. the INVIDIa study

MAZZONI, FEDERICO;Papa A.;LOLLI, CRISTINA;Milella M.;Vitale M. G.;Massari F.;Facchini G.;Tomao S.;Vaccaro V.;Maestri A.;Natoli C.;PIREDDU, ANNAGRAZIA;Comito F.;
2018

Abstract

Aim: Considering the unmet need for the counseling of cancer patients treated with immune checkpoint inhibitors (CKI) about influenza vaccination, an explorative study was planned to assess flu vaccine efficacy in this population. Methods: INVIDIa was a retrospective, multicenter study, enrolling consecutive advanced cancer outpatients receiving CKI during the influenza season 2016-2017. Results: Of 300 patients, 79 received flu vaccine. The incidence of influenza syndrome was 24.1% among vaccinated, versus 11.8% of controls; odds ratio: 2.4; 95% CI: 1.23-4.59; p = 0.009. The clinical ineffectiveness of vaccine was more pronounced among elderly: 37.8% among vaccinated patients, versus 6.1% of unvaccinated, odds ratio: 9.28; 95% CI: 2.77-31.14; p < 0.0001. Conclusion: Although influenza vaccine may be clinically ineffective in advanced cancer patients receiving CKI, it seems not to negatively impact the efficacy of anticancer therapy.
2018
Immune checkpoint inhibitors; influenza syndrome; influenza vaccine; antibodies monoclonal; costimulatory and inhibitory T-cell receptors; female; follow-up studies; humans; immunotherapy; incidence; influenza A virus; influenza vaccines; influenza human; Italy; male; neoplasms; retrospective studies; vaccination
01 Pubblicazione su rivista::01a Articolo in rivista
INfluenza vaccine indication during therapy with Immune checkpoint inhibitors: a transversal challenge. the INVIDIa study / Bersanelli, M.; Giannarelli, D.; Castrignano, P.; Fornarini, G.; Panni, S.; Mazzoni, Federico; Tiseo, M.; Rossetti, S.; Gambale, E.; Rossi, E.; Papa, A.; Cortellini, A.; Lolli, Cristina; Ratta, R.; Michiara, M.; Milella, M.; Luca, E. D.; Soraru, M.; Mucciarini, C.; Atzori, F.; Banna, G. L.; Torre, L. L.; Vitale, M. G.; Massari, F.; Rebuzzi, S. E.; Facchini, G.; Schinzari, G.; Tomao, S.; Bui, S.; Vaccaro, V.; Procopio, G.; Giorgi, U. D.; Santoni, M.; Ficorella, C.; Sabbatini, R.; Maestri, A.; Natoli, C.; Tursi, M. D.; Maio, M. D.; Rapacchi, E.; Pireddu, Annagrazia; Sava, T.; Lipari, H.; Comito, F.; Verzoni, E.; Leonardi, F.; Buti, S.. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - 10:14(2018), pp. 1229-1239. [10.2217/imt-2018-0080]
File allegati a questo prodotto
File Dimensione Formato  
Bersanelli_INfluenza Vaccine Indication_2018.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 995.09 kB
Formato Adobe PDF
995.09 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1317175
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 38
social impact